Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.

Advertisement

Related Content

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines
Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated
Novartis Pulling Out All The Stops To Amp Up Entresto Sales
Keeping Track: Approvals Aplenty As FDA Clears Taltz, Cinqair And Anthim
EU Committee Nod For Lilly's Ixekizumab In Psoriasis

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS079241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel